Anti-CD20 therapy reduces microglial activation and lesion volume in focal models of pattern I and pattern II multiple sclerosis

被引：0
|
作者：
Anthony, D. C.
Campbell, S. J.
Seneca, N.
Balazs, M.
Leppert, D.
机构：
[1] Univ Oxford, Oxford, England
[2] Roche, Basel, Switzerland
[3] Genentech Inc, San Francisco, CA 94080 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P734
引用
收藏
页码：S325 / S326
页数：2
相关论文
共 50 条
  • [31] Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes"
    Rolfes, Leoni
    Meuth, Sven G.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 691 - 693
  • [32] Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary
    Gratch, Daniel
    Zhovtis Ryerson, Lana
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 695 - 696
  • [33] Neutropaenia complicating anti-CD20 therapy in Multiple Sclerosis: A retrospective review of cases in South-East London and Kent
    Paranavitane, Shiran
    Harikrishnan, Sreedharan
    Silber, Eli
    Brex, Peter
    Williams, Victoria
    Falah, Yasser
    Raftopoulos, Rhian
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1025 - 1026
  • [34] Efficacy of Accelerated Vaccination against Hbv to Achieve Antibody formation in Multiple Sclerosis Patients Receiving Anti-Cd20 Therapy
    Koc, Emine Rabia
    Turan, Omer Faruk
    Saridas, Furkan
    Menguc, Bedirhan
    Minaz, Sema Nur
    Ozkaya, Guven
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2023, 26 (05) : 697 - 701
  • [35] Safety and efficacy of cladribine therapy following a treatment with anti-CD20 compounds in relapsing multiple sclerosis patients: a pilot study
    Sacco, R.
    Disanto, G.
    Pravata, E.
    Gobbi, C.
    Zecca, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 852 - 852
  • [36] Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis
    Novak, Frederik
    Nilsson, Anna Christine
    Nielsen, Christian
    Holm, Dorte K.
    ostergaard, Kamilla
    Bystrup, Anna
    Byg, Keld-Erik
    Johansen, Isik S.
    Mittl, Kristen
    Rowles, William
    Mcpolin, Kira
    Spencer, Collin
    Sagan, Sharon
    Gerungan, Chloe
    Wilson, Michael R.
    Zamvil, Scott S.
    Bove, Riley
    Sabatino, Joseph J.
    Sejbaek, Tobias
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
  • [37] Effects of anti-CD20 monoclonal antibody therapy on cerebrospinal fluid B cell subsets in relapsing-remitting multiple sclerosis
    El Mahdaoui, S.
    Hansen, M. M.
    von Essen, M.
    Sellebjerg, F.
    Christensen, J. Romme
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 840 - 840
  • [38] Functional Characterization of Reappearing B cells After Anti-CD20 Mediated B cell Depletion in Two Animal Models of Multiple Sclerosis
    Haeusler, Darius
    Haeusser-Kinzel, Silke
    Feldmann, Linda
    Torke, Sebastian
    Lepennetier, Gildas
    Bernard, Claude C. A.
    Zamvil, Scott S.
    Brueck, Wolfgang
    Lehmann-Horn, Klaus
    Weber, Martin S.
    NEUROLOGY, 2019, 92 (15)
  • [39] Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles (vol 14, 1158487, 2023)
    Fong, Chloe C.
    Spencer, Julian
    Howlett-Prieto, Quentin
    Feng, Xuan
    Reder, Anthony T.
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [40] Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
    Gadani, Sachin P.
    Reyes-Mantilla, Maria
    Jank, Larissa
    Harris, Samantha
    Douglas, Morgan
    Smith, Matthew D.
    Calabresi, Peter A.
    Mowry, Ellen M.
    Fitzgerald, Kathryn C.
    Bhargava, Pavan
    EBIOMEDICINE, 2021, 73
12345